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Objectives: Throughout Europe, economic conditions are forcing health care sys-
tems to reduce costs. One primary driver of health care costs is hospital length of 
stay (LOS). This study sought to determine which European countries have been 
most successful at reducing their average LOS for five inpatient admissions. This 
research also sought to quantify the potential savings for countries that have 
not been as successful in reducing their average LOS if they can align with their 
peers. MethOds: A review of hospital LOS and cost per day of hospital stay data 
was conducted in five European countries (France, Germany, Italy, Spain and the 
United Kingdom), utilizing data published by the World Health Organization (WHO). 
Additionally, hospital payment systems were assessed in each country through 
published research to understand systemic motivations of health care providers 
with regards to LOS. Results: Substantial variability exists in average LOS for the 
studied admissions. The greatest variability was in breast cancer, with average stays 
ranging from 4.36 days in the UK to 11.01 days in Germany. The average LOS for three 
admissions (single spontaneous delivery, cataracts, and pneumonia) are relatively 
similar across countries. However, the average LOS in Germany for malignant neo-
plasm of the breast and acute myocardial infarction are significantly higher than 
the other four countries. There is little variability, however, in average costs per 
bed-day in the target countries. A review of payment mechanisms for inpatient 
stays revealed that hospitals are financially incentivized to minimize LOS in all five 
countries. cOnclusiOns: Additional research is needed to understand the reason 
for the discrepancy between German stays and the other four countries. While there 
are many potential reasons for the differences, should Germany align their average 
LOS for malignant neoplasm of the breast and acute myocardial infarction with the 
other four countries, they could save € 744 million per year.
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Objectives: The pharmaceutical industry is in the center of political debate due 
to their high profitability. In this study, we argue that abnormal profitability in the 
pharmaceutical industry is a kind of optical illusion created by accounting stand-
ards and their influence on reported accounting profit and book equity – the two 
components of ROE. The internationally accepted accounting frameworks either 
do not permit capitalizing R&D investments as U. S. GAAP or limit capitalizing R&D 
investments as International Financial Reporting Standards (IFRS) applicable in 
the E. U. and most countries. This treatment understates assets and equity, and 
can overstate reported profit because relevant cost components (amortization of 
R&D) are not deducted from revenues they generate. We empirically aim to esti-
mate the magnitude of this accounting bias. MethOds: Based on international 
financial data of 413 pharmaceutical firms between 1972 and 2012, we assessed 
the “true” profitability of pharmaceutical firms by capitalizing R&D and amortizing 
it over the shelf-life of developed products. We use three amortization approaches 
(linear amortization, declining-balance amortization and amortization based 
on the empirical amortization rates). Results: Corrected profit and equity 
figures lead to substantially lower long-term profitability of pharmaceutical 
firms. Over the three proposed amortization approaches, the corrected ROE of 
14.1% is comparable to profitability reported by U. S. firms from other indus-
tries (ROE = 11.1%). Non-U. S. pharmaceutical firms also have an adjusted ROE 
that is comparable to firms from other industries (7.6% pharma vs. 9.6% non-
pharma). cOnclusiOns: The policy implication of our study is that price regula-
tion or rate of return regulation in the pharmaceutical market should be reviewed 
and applied with caution when it is solely motivated by the allegedly high profit-
ability of the industry. This is especially true since such a policy also impedes 
R&D investments and innovation in the long run because profits serve as a major 
source of R&D investments.
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Objectives: Specialty drugs are often many times more expensive than traditional 
drugs, raising questions of affordability, and whether their clinical benefits are 
worth their added costs. The objective of this study was to consider new molecular 
entities (NME) (i. e., drugs that had not previously been approved by the FDA or 
marketed in the US) approved by the FDA from 1999 through 2011 to compare the 
value of specialty and traditional drugs. MethOds: We searched the FDA website 
to identify all NMEs approved from 1999 through 2011. We identified published esti-
mates of additional health gains (measured in quality adjusted life years (QALYs)) 
and costs (drug costs, hospitalization costs, etc) associated with specialty drugs 
compared to existing standard of care at their time of approval, and compared 
findings with traditional drugs. We compared incremental QALY gains, incremen-
tal costs, and the incremental cost-effectiveness ratio, for specialty vs. traditional 
drugs using a Mann Whitney U test. Results: We identified relevant estimates 
of additional health gains and costs for 101 (36%) of NMEs, including 59 specialty 
drugs. We found specialty drugs offered greater QALY gains than traditional drugs 
(0.19 vs. 0.01, p< 0.01), but were associated with greater additional costs ($10,460 
vs. $906, p< 0.01). We found the cost-effectiveness of the different drug types to be 
broadly similar (p= 0.58). cOnclusiOns: This research suggests specialty drugs 
may offer greater health benefits over existing care than traditional drugs, and 
despite specialty drugs being associated with greater costs, specialty and traditional 
drugs were comparable in terms of cost-effectiveness. As payers search for ways to 
control health care costs it is important to recognize the relative benefits as well as 
the costs of specialty drugs, and to mitigate inappropriate use and waste to ensure 
that effective treatments are affordable to patients.
Analytics MarketScan® database, inpatient costs from the Healthcare Cost and 
Utilization Project (HCUP) and costs reported for Ambulatory Patient Classifications 
(APC) were used to estimate costs from the hospital perspective. Results: 13,463 
patients were evaluated. Rates of patients experiencing any complication were 
17.3% within 30 days, 11.0% within 31-60 days, 8.1% within 61-90 days, and 21.4% 
within 91 days – 12 months. In total, 37.8% of patients experienced a complication 
over 12 months. The most frequent complications over 12 months were infection 
(16.6%), bowel obstruction/ other GI complication (12.6%), skin/connective tissue-
related complications (10.7%), and wound complications (8.1%). Complication-
related cost over time followed a similar trend; average 12 month cost for patients 
experiencing an infection was $20,679, $21,558 for bowel-related complications, 
$14,950 for skin/ connective tissue related complications and $19,230 for wound 
complications. The index event average length of stay for patients with no complica-
tions and patients with complications was 3.9 (sd 4.4) and 17.0 (sd 19.6), respectively; 
p< 0.0001. cOnclusiOns: Health care resource utilization, costs and complications 
for complex abdominal wall reconstruction patients increase over time. Resource 
utilization is exacerbated when complications occur. Further study may be required 
to validate these findings.
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Many people in Ireland suffer from chronic diseases including AF, diabetes, COPD 
and asthma. With the prevalence of these conditions expected to rise, general 
wellbeing and quality-of-life will be increasingly affected. Chronic conditions also 
account for most of the health care resources used, and represent a significant 
economic burden for Ireland in the future. Objectives: Estimate the number of 
preventable disease associated events and costs associated with poor management 
of patients with AF, diabetes, COPD and asthma. MethOds: For each province, 
calculate the number of patients diagnosed with AF, diabetes, COPD or asthma, 
based on disease prevalence and 2011 Census data. Estimate the number of patients 
not achieving target management of their condition and the associated number of 
preventable events and total costs, using publically available information. Results: 
Of the approximately 59,647 patients diagnosed with AF in Ireland, 23,561 patients 
are not receiving appropriate anticoagulation treatment. This results in 531 patients 
experiencing an avoidable stroke each year, costing the health care system around 
€ 9.3m. Amongst the 238,589 patients diagnosed with type 2 diabetes, 77% will not 
achieve a target HbA1c of 6.5% or less, resulting in an expense of € 886m and 12,493 
avoidable deaths each year. In addition, 30% of diagnosed COPD patients, and as 
many as 60% of asthma patients, are not managing their condition effectively, 
costing the Irish health care system € 899m per year in hospital admission costs 
alone. cOnclusiOns: Much of the chronic disease burden is caused by preventable 
risk factors. This is intended as a key policy lever, to elevate chronic diseases on the 
health agenda of key policymakers, providing them with better evidence about risk 
factor control, and persuading them of the need for health systems change. Unless 
steps are taken now to effectively deal with chronic diseases, Ireland is headed for 
serious financial and quality-of-life crises.
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Objectives: As health care costs continue to rise, employers seek options to improve 
the health and wellness of their employees. This study examined the practices of 
employers that are actively engaged in promoting employee health. MethOds: 
A study of 18 employers who applied for the Working Well award provided by the 
Louisiana Business Group on Health in 2013, recognizing employers who are exem-
plar in their employee health and wellness activities. Applicants completed a survey 
detailing business policies and programs intended to promote wellness. De-identified 
data derive from 2013 applications. Results: Over half of the companies had fewer 
than 500 employees (55.6%), 4 had more than 2000. Health plan coverage was fully (8; 
44.4%) or self (7; 38.9%) funded. Almost half implemented wellness programs within 
the last 3 years (44.4%), whereas 4 (22.2%) had programs more than 10 years; all were 
company funded. Annual spend on wellness was split across participating employ-
ers with 55.6% spending < $50,000 and the rest > $50,000 (8; 44.4%). Rationale most 
cited for programs: improve employee wellbeing (18; 100%), contain health care costs 
(17; 94.4%), increase productivity (13; 72.2%), and reduce absenteeism (12; 66.7%). 
Most employers incentivized program participation (16; 88.9%) through premium 
reductions (8; 44.4%), cash (8; 44.4%), or PTO (3; 16.7%). Information most reported 
to help with wellness planning were health risk assessments (HRAs) (15; 83.3%), 
health care claims and utilization (14; 77.8%), and worker’s compensation claims 
(8; 44.4%). cOnclusiOns: In the US, employers are responsible for a significant por-
tion of health care spend. Though a small self-selected sample, this analysis reveals 
that employers actively engaging their employees, using prevention and incentives 
to promote wellness are a more recent occurrence. The trend suggests increasing 
awareness that efforts to improve employee health and wellness can help attract 
and retain staff, as well as potentially reducing health care costs.
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that setting arbitrary benchmarks based on empirical observation of compara-
tive EU countries is incorrect due to wide inconsistencies over pharmaceutical 
distribution.
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Objectives: In Ireland, the reimbursement decision process involves the Marketing 
Authorisation Holder (MAH) submitting a Health Technology Assessment (HTA) dos-
sier to the National Centre for Pharmacoeconomics (NCPE). The NCPE evaluates 
this dossier and submits a reimbursement recommendation to the Health Service 
Executive (HSE) (the decision maker). Along with Cost-Effectiveness and Budget 
Impact analyses, the decision maker considers other criteria in determining the 
health benefit of an intervention. Those interventions which are not deemed cost 
effective at a threshold of € 45,000/QALY may proceed to HTA informed HSE-MAH 
price negotiations. The aim of this study was to estimate the potential annual cost 
savings (reduced potential budget impacts) to the HSE as a consequence of HTA 
informed price negotiations. MethOds: All NCPE assessments received over a 2 
year period were reviewed. Interventions were included if initially they had not been 
recommended for reimbursement, but had subsequently been reimbursed after 
HTA informed price negotiations. The potential total annual cost saving to the HSE 
(difference between the original Gross BI (submitted price) and the revised Gross 
BI (negotiated price) was estimated. The respective MAH BI models were used for 
these analyses. Results: Eight interventions fitted the inclusion criteria; all were 
classified as either oncology drugs or drugs for orphan diseases. When all such 
drugs are considered, it is estimated that the cost savings to the HSE, as a result of 
HTA informed price negotiations is over € 19 million per annum. cOnclusiOns: 
In Ireland, HTA informed price negotiations lead to considerable cost savings to 
the Health Payer.
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Objectives: - To assess access to NCD medicine in India using public drug procure-
ment data. MethOds: - State procurement data was used to calculate, total and per 
capita value of procurement towards purchase of essential medicines. ABC analysis 
was performed to identify priority medicines that together account for 80% of total 
expenditure (Category A items). The proportion of NCD medicines among category A 
items was then estimated. Finally, the efficiency of the system was captured through 
comparative price analysis of procurement price to International Reference Price 
(IRP). Results: - Out of the 91 NCD medicines on WHO list of essential medicine, 
states were procuring 40 to 87 NCD medicines. In addition, the share of NCD pro-
curement value to total procurement value was in range of 1.32% to 37%. Similarly, 
the annual per capita spending was in range of 0.1 to 103 Indian Rupees (INR). 
The procurement prices across all the states were lower than the international 
reference price. The retail market prices were between 45%-3600% higher than the 
state procurement prices, and were higher on average by 6 times of international 
reference price. The defined daily dose estimates were not uniform for all ATC. The 
most neglected category among all ATC’s was mental health, in the range of 0.020-
56.688 DDD per 1000. cOnclusiOns: - There is limited access to NCD medicines 
in public health system in selected Indian states.
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Objectives: To construct a comorbidity index according to iso-consumption of 
health resources and their associated costs in routine clinical practice. MethOds: 
We made a multicentre study through review of computerized medical records. 
The study population consisted of patients assigned to seven primary care centres, 
two acute care hospitals and one social health centre, allmanaged by Badalona 
ServeisAssistencials SA. The following variables were analysed: age (0-100 years), 
sex, comorbidity (chronic diagnoses) and direct health care costs. We estimated 
the resource use and gross health care costs attributed to all patients requiring 
health care in 2013. Subsequently, an expert panel identified the most-prevalent 
chronic diseases (ICD-9). Subgroups were established according to age and number 
of chronic comorbidities. The main variables and comorbidities associated with 
the costs were identified using a multivariate model. This allowed a total score to 
be developed for each patient. Statistical analysis: Spearman’s correlation coef-
ficient, multiple logistic models and linear regression were used. A value of p < 0.05 
was identified as significant. Results: We recruited 103,764 patients (86.5% of the 
total). Mean age was 43.1 (23.9) years and 52.4% were female. The mean unit cost 
was € 836.9 (2032). The gross cost was associated with age (r = 44.8) and comor-
bidity (r = 0.512). The final score was obtained from the logistic model. The score 
obtained showed a good correlation with age (r = 81.8), comorbidity (r = 0.939) 
and the cost of health care (r = 0.696). The index obtained explained 44.7% of the 
gross cost. The index was better adapted to the adjusted costs. We describe the 
disaggregated results and the results according to levels of comorbidity (healthy, 
low, medium, high). cOnclusiOns: The comorbidity index obtained was shown 
to be a simple potential predictor of the cost of care and may be applied in routine 
clinical practice.
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Objectives: The pace of innovation in health care has facilitated gains in life 
expectancy, but at a tremendous cost. Rational use of limited health care resources 
remains one of the greatest challenges in health care worldwide. This analysis 
sought to compare health care spending and health outcomes in countries with 
and without formal health technology assessment programs. MethOds: Data 
was collected on health care spending from 1990-2012 in European countries with 
and without HTA and compared to the United States, which eschews any formal 
evaluation of comparative or cost effectiveness. Measures of health outcomes were 
considered, including life expectancy and overall mortality. The impact of popula-
tion age, tobacco use and obesity rates on health outcomes were considered. Lastly, 
the number, content and methodology of HTA publications in countries with HTA 
were assessed. Results: The majority of HTA evaluations have focused on phar-
maceuticals. Countries with established HTA had lower spending on pharmaceu-
ticals, but not always lower overall health care spending, while maintaining or 
improving health outcomes relative to non-HTA countries. The United States had 
the highest rate and annual increase in rate in pharmaceutical spending as well as 
overall health care spending, with the worst health care outcomes in countries ana-
lyzed. cOnclusiOns: The incorporation of formal health technology assessment as 
part of overall health care decision making appears to assist in controlling the rise 
in health care spending, particularly drug spending. While better health outcomes 
in life expectancy and mortality were found in HTA versus non-HTA countries, 
correlation versus causality can only be considered at this point. Systematic use of 
HTA on both pharmaceutical and non-pharmaceutical interventions may help to 
control overall health care spending.
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Objectives: Health Transformation Program was started at year 2002 by Ministry of 
Health (MoH) in Turkey. Today, Turkey has a well established health system mostly 
dominated by government on health care provider and payer. The program allows 
the patient access to all drugs. There was an increasing trend for the pharmaceu-
tical consumption in years depending on the taken policies as other health care 
services. The aim of this study is to review an analysis for the new drug release 
prices for Turkey in the recent years. MethOds: The data was obtained from the 
last price list of each calender year published by MoH for the years between 2009-
2014. The year 2014 year data limited with the first quarter (Q1). The data classified 
in three groups which were; over 100 TL, over 1000 TL and over 10000 TL. All the 
result were based on ex-factory prices. A descriptive analysis was conducted on 
the price lists with the number of the products, maximum and average ex-factory 
prices. Results: The numbers of new released products over 100 TL were; 1, 7, 58, 
36 and 52 in the years 2009, 2010, 2011, 2012 and 2013, respectively. The numbers 
of new released products over 1000 TL were; 0, 1, 10, 11 and 13 in the years 2009, 
2010, 2011, 2012 and 2013, respectively. The highest ex-factory prices were 739 TL, 
1117 TL, 4066, 72 TL, 5781, 05 TL, 22791, 55 TLand 36577, 33 in the years 2009, 2010, 
2011, 2012 and 2013, respectively. The average ex-factory prices were 178, 98 TL, 329, 
28 TL, 214, 36 TL, 312, 93, 497, 44 TL and 612, 85 TL in the years 2009, 2010, 2011, 2012, 
2013 and 2014Q1 respectively. cOnclusiOns: It was shown that the number of 
high prices drugs, the highest price and the average price of the new drugs were 
increased year by year. Increased patient access may encoruage pharmaceutical 
companies to enter the Turkish market with their innovative drugs which have high 
price tag compared to regular drugs.
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Objectives: The 2008 global financial crisis hit Portugal strongly culminating 
in request financial assistance from European Union and International 
Monetary Fund on 17th May of 2011. In addition, Portuguese economy had already 
before 2008 a decreasing real growth rate of GDP, stagnant from early in the dec-
ade, and an increasing external deficit. Health care measures represented a key 
area within the assistance program. Specific targets were set for public spend-
ing in pharmaceuticals in order to align with EU average at 1.25 and 1.0 percent 
of GPD for 2012 and 2013, respectively. The aim of our study was to demonstrate 
that GDP targets was a political decision not supported by evidence, techni-
cally inaccurate, created a hurdle and equity asymmetries for patients access to 
medications, as well as jeopardized the future sustainability of Pharmaceutical 
sector. MethOds: We analyzed health, pharmaceuticals and medicines public 
spending EU benchmark in real terms, GDP ratio and per capita. We also revise 
the System of Health Accounts methodology and conceptual framework of 
International Classification of Health Accounts. OECD definitions, sources and 
methods were also studied. Results: Despite the efforts to improve the com-
parability across countries through common and better information framework 
of greater relevance for policy concerns, we observed that such approach is not 
recommended. For a more comprehensive understanding of health spending in 
relation to GDP ratio, it should be considered together with health spending per 
capita. Portugal comparisons are an OECD example for this rational. Importantly, 
OECD measures of pharmaceutical spending exclude in-patient (hospital) spend-
ing. In addition, pharmaceuticals definition is broader than prescription medicines 
only. cOnclusiOns: Important political decisions were taken assuming pharma-
ceuticals and prescription medicines as the same concept. Here, we demonstrate 
